View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 20, 2020

Australian team develops blood test to detect Covid-19 in 20 minutes

A research team led by Monash University in Australia has invented a blood test that can detect a positive Covid-19 result in 20 minutes.

A research team led by Monash University in Australia has invented a blood test that can detect a positive Covid-19 result in 20 minutes.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The research team was led by BioPRIA and the university’s chemical engineering department, including researchers from the ARC Centre of Excellence in Convergent BioNano Science and Technology (CBNS).

Designed as an agglutination assay, the test is based on common blood typing infrastructure. It was able to identify recent cases of Covid-19 with 25 microlitres of plasma from blood samples.

An agglutination assay is used to analyse for the presence and amount of a substance in the blood. The new test can detect the presence of antibodies generated in response to SARS-CoV-2, the virus that causes Covid-19, said the researchers.

The virus causes an agglutination or a clustering of red blood cells that can be seen by the naked eye, enabling the team to determine positive or negative test results in approximately 20 minutes.

Existing swab / polymerase chain reaction (PCR) tests can identify individuals who are currently positive with Covid-19. The new test can determine if someone is currently infected and if they have been previously infected.

In addition, the agglutination assay has the potential to support clinical trials by identifying antibodies produced in response to vaccination.

Medical practitioners will be able to use the test to analyse up to 200-700 blood samples an hour, noted the researchers.

Apart from population screening and case identification, the test is expected to help high-risk countries in contact tracing, vaccine efficacy confirmation in clinical trials and vaccine distribution.

CBNS chief investigator and Monash University chemical engineering senior lecturer Dr Simon Corrie said: “This simple assay, based on commonly used blood typing infrastructure and already manufactured at scale, can be rolled out rapidly across Australia and beyond.

“This test can be used in any lab that has blood typing infrastructure, which is extremely common across the world.”

The researchers have filed a patent for the invention and are seeking commercial and government support to scale up production.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network